Clinical Trial Update: Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells [Phase 1]

View source ↗

Summary

Phase 1 trial of autologous tumor cells engineered to express human IL-2 and CD40 ligand for chronic lymphocytic leukemia. The study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Autologous IL-2 and CD40 ligand–expressing tumor cell vaccine

Snippet

Sponsor: Baylor College of Medicine | Conditions: CHRONIC LYMPHOCYTIC B-LEUKEMIA | Phase 1 | Status: WITHDRAWN